GILD vs. ILMN: Gilead Sciences vs. Illumina Stock Comparison

Company Profile

Gilead Sciences (GILD) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Gilead Sciences (GILD) is defensive at 0.36 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Gilead Sciences (GILD) at 2.39% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Illumina (ILMN) at 0.74 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Illumina (ILMN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

Illumina (ILMN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.

Valuation Metrics